Capital World Investors
RAPP

Capital World Investors’s Rapport Therapeutics RAPP Stock Holding History

Capital World Investors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23M Buy
551,657
+15,050
+3% +$553K ﹤0.01% 546
2026
Q1 		$16.8M Buy
+536,607
New +$15.1M ﹤0.01% 540

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Capital World Investors's RAPP Position: Q2 2026 in Review

Capital World Investors increased its Rapport Therapeutics (RAPP) stake by 2.8% in Q2 2026, buying an estimated $553K and bringing the position to 551,657 shares worth $23M. The position accounts for ﹤0.01% of the portfolio, ranked #546.

Capital World Investors first reported a position in RAPP in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Capital World Investors held 551,657 shares of Rapport Therapeutics worth $23M as of Q2 2026.
  • Capital World Investors bought 15,050 Rapport Therapeutics shares in Q2 2026, an estimated $553K.
  • Rapport Therapeutics made up ﹤0.01% of Capital World Investors's portfolio in Q2 2026, its #546 holding.
  • Capital World Investors first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.